Nevertheless, all major scientific societies endorse its use in children with mild-to-moderate non-IgE-mediated CMPA (defined as mild gastrointestinal and/or skin symptoms, e.g., irritability, constipation, mild diarrhea, abdominal discomfort, pruritus, erythema, rash, moderate atopic dermatitis). The gene discussed is IGHE; the disease is atopic eczema.